Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Current Neurology and Neuroscience Reports
Erschienen in: Current Neurology and Neuroscience Reports 2/2016

01.02.2016 | Neuro-oncology (L. E. Abrey, Section Editor)

Nitrosoureas in the Management of Malignant Gliomas

verfasst von: Alba A. Brandes, Marco Bartolotti, Alicia Tosoni, Enrico Franceschi

Erschienen in: Current Neurology and Neuroscience Reports | Ausgabe 2/2016

Einloggen, um Zugang zu erhalten

Abstract

Nitrosoureas represent one of the most active classes of agents in the treatment of high-grade gliomas and glioblastoma. In clinical practice, the most commonly used compounds are lomustine (either alone or in combination with procarbazine and vincristine), carmustine, and fotemustine. Given their toxicity profile and subsequent to the introduction of temozolomide in clinical practice, most of these agents were moved to the recurrent setting. This review focuses on the role of the nitrosoureas currently used in clinical practice for the treatment of malignant gliomas.
Literatur
1.
DeVita VT, et al. Rosenberg, Steven A. Devita, Hellman, and Rosenberg’s cancer: principles & practice of oncology. Philadelphia: Wolters Kluwer. Second edition. Pp 372–373
2.•
Stewart LA. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet. 2002;359(9311):1011–8. Meta-analysis showing the survival improvement obtained with nitrosoureas in newly-diagnosed high-grade gliomas.CrossRefPubMed
3.•
Walker MD et al. Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med. 1980;303(23):1323–9. Randomized trial that showed the survival advantage of BCNU plus RT over RT alone in newly-diagnosed GBM.CrossRefPubMed
4.
Brandes AA et al. Early chemotherapy and concurrent radio-chemotherapy in high grade glioma. J Neurooncol. 1996;30(3):247–55.CrossRefPubMed
5.
van den Bent MJ et al. Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034. J Clin Oncol. 2009;27(8):1268–74.PubMedCentralCrossRefPubMed
6.
Brandes AA et al. How effective is BCNU in recurrent glioblastoma in the modern era? A phase II trial. Neurology. 2004;63(7):1281–4.CrossRefPubMed
7.
8.
Brandes AA et al. Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first-line temozolomide chemotherapy: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). J Clin Oncol. 2004;22(23):4779–86.CrossRefPubMed
9.
Levin VA et al. Nitrosourea chemotherapy for primary malignant gliomas. Cancer Treat Rep. 1976;60:719–24.PubMed
10.
Shapiro WR et al. Chemotherapy of malignant glioma with CCNU alone and CCNU combined with vincristine sulfate and procarbazine hydrochloride. Trans Am Neurol Assoc. 1976;101:217–20.PubMed
11.
E.O.R.T.C. Brain Tumor Group. Effect of CCNU on survival rate of objective remission and duration of free interval in patients with malignant brain glioma--final evaluation. Eur J Cancer. 1978;14(8):851–6.CrossRef
12.
Eyre HJ et al. Randomized comparisons of radiotherapy and CCNU versus radiotherapy, CCNU plus procarbazine for the treatment of malignant gliomas following surgery. A Southwest Oncology Group Report. J Neurooncol. 1983;1(3):171–7.CrossRefPubMed
13.
Levin VA. Chemotherapy of primary brain tumors. In: Frank BD, editor. Symposium on Neuro-oncology, vol 3, Neurologic Clinics. 4th ed. York, Penn: WB Saunders; 1985. p. 855–66.
14.•
Levin VA et al. Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report. J Radiat Oncol Biol Phys. 1990;18:321–4. This study showed the survival advantage of PCV over BCNU as post-RT adjuvant therapy in high-grade gliomas.CrossRef
15.
Levin VA et al. Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report. J Radiat Oncol Biol Phys. 1990;18:321–4.CrossRef
16.
Stupp R et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987–96.CrossRefPubMed
17.
Wick W, Puduvalli VK, Chamberlain MC, et al. Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. J Clin Oncol. 2010;28(7):1168–74.PubMedCentralCrossRefPubMed
18.
Batchelor T et al. The efficacy of cediranib as monotherapy and in combination with lomustine compared to lomustine alone in patients with recurrent glioblastoma: a phase III randomized trial. J Clin Oncol. 2013;31:3212–8.PubMedCentralCrossRefPubMed
19.
Taal W et al. Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. Lancet Oncol. 2014;15:943–53.CrossRefPubMed
20.•
Brandes AA et al. Fotemustine as second-line treatment for recurrent or progressive glioblastoma after concomitant and/or adjuvant temozolomide: a phase II trial of Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). Cancer Chemother Pharmacol. 2009;64(4):769–75. This study showed the activity of fotemustine in recurrent GBM.PubMedCentralCrossRefPubMed
21.
Addeo R et al. A new schedule of fotemustine in temozolomide-pretreated patients with relapsing glioblastoma. J Neurooncol. 2011;102(3):417–24.PubMedCentralCrossRefPubMed
22.
Brandes A et al. Randomized phase II trial AVAREG (ML25739) with bevacizumab (BEV) or fotemustine (FTM) in recurrent glioblastoma: final results from the randomized phase II trial. Ann Oncol. 2014;25 suppl 4:iv137.
23.
Cairncross G et al. Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol. 2006;24:2707–14.CrossRefPubMed
24.
van den Bent MJ et al. Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. J Clin Oncol. 2006;24:2715–22.CrossRefPubMed
25.•
Wick W et al. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J Clin Oncol. 2009;27(35):5874–80. A randomized phase III trial that compares upfront treatment with RT or chemotherapy (PCV or temozolomide) in anaplastic gliomas.CrossRefPubMed
26.•
Cairncross G et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J Clin Oncol. 2013;31(3):337–43. A randomized phase III trial that compared RT alone versus RT plus PCV as adjuvant treatment for AOD and AOA.PubMedCentralCrossRefPubMed
27.••
van den Bent MJ et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. J Clin Oncol. 2013;31(3):344–50. This study showed an advantage in OS with the addition of PCV to standard radiotherapy in AO and AOA.CrossRefPubMed
28.
van den Bent MJ et al. MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951. J Clin Oncol. 2009;27(35):5881–6.PubMedCentralCrossRefPubMed
29.
van den Bent MJ et al. IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group. Clin Cancer Res. 2010;16(5):1597–604.CrossRefPubMed
30.
Wick W, et al. Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide. J Clin Oncol. 2015;33(suppl; abstr 2001)
31.
Cairncross G et al. Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 1994;12:2013–21.PubMed
32.
van den Bent MJ et al. Response rate and prognostic factors of recurrent oligodendroglioma treated with procarbazine, CCNU, and vincristine chemotherapy. Dutch Neuro-Oncol Group Neurol. 1998;51:1140–5.
33.•
Brada M et al. Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade glioma. J Clin Oncol. 2010;28(30):4601–8. A trial comparing temozolomide versus PCV in recurrent high-grade gliomas.CrossRefPubMed
34.
Fernández-Hidalgo OA et al. High-dose BCNU and autologous progenitor cell transplantation given with intra-arterial cisplatinum and simultaneous radiotherapy in the treatment of high-grade gliomas: benefit for selected patients. Bone Marrow Transplant. 1996;18(1):143–9.PubMed
35.
Jakacki RI et al. Dose-intensive, time-compressed procarbazine, CCNU, vincristine (PCV) with peripheral blood stem cell support and concurrent radiation in patients with newly diagnosed high-grade gliomas. J Neurooncol. 1999;44(1):77–83.CrossRefPubMed
Metadaten
Titel
Nitrosoureas in the Management of Malignant Gliomas
verfasst von
Alba A. Brandes
Marco Bartolotti
Alicia Tosoni
Enrico Franceschi
Publikationsdatum
01.02.2016
Verlag
Springer US
Erschienen in
Current Neurology and Neuroscience Reports / Ausgabe 2/2016
Print ISSN: 1528-4042
Elektronische ISSN: 1534-6293
DOI
https://doi.org/10.1007/s11910-015-0611-8

Weitere Artikel der Ausgabe 2/2016

Current Neurology and Neuroscience Reports 2/2016 Zur Ausgabe

Neurology of Systemic Diseases (J Biller, Section Editor)

Neurocutaneous Disorders for the Practicing Neurologist: a Focused Review

Epilepsy (C. W. Bazil, Section Editors)

Neurogenesis in the Hippocampus of Patients with Temporal Lobe Epilepsy

Infection (J Halperin, Section Editor)

Developments in Varicella Zoster Virus Vasculopathy

Neuro-Ophthalmology (A Kawasaki, Section Editor)

Optic Perineuritis

Headache (R. B. Halker, Section Editor)

Non-Invasive Neuromodulation for Headache Disorders

Neuro-oncology (L A Abrey, Section Editor)

Emerging Approaches for Targeting Metabolic Vulnerabilities in Malignant Glioma

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise